Summary
=======

A 77-year-old male underwent elective bioprosthetic aortic valve replacement (23 mm Carpentier-Edwards Perimount MagnaEase) for severe aortic stenosis. His pre-discharge transthoracic echocardiogram (TTE) was normal. He presented 9 days after surgery with dyspnea and fever. He was in sinus rhythm. Blood cultures were taken and he was commenced on empirical antibiotics for possible infective endocarditis (subsequently all negative). Repeat TTE showed a well-seated prosthesis without regurgitation but elevated gradients (peak/mean gradients 69/48mmHg respectively). Transoesophageal echocardiography (TOE) revealed marked thickening of the leaflets, without obvious vegetations ([Fig. 1](#fig1){ref-type="fig"} and [Videos 1](#SM1){ref-type="supplementary-material"}, [2](#SM2){ref-type="supplementary-material"}). The patient was diagnosed with subacute prosthetic valve thrombosis and was anticoagulated with apixaban. He underwent repeat TOE 3 months later, which demonstrated thin, mobile valve leaflets with normalized transprosthetic gradients ([Figs 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"} and [Videos 3](#SM3){ref-type="supplementary-material"}, [4](#SM4){ref-type="supplementary-material"}). Thrombosis of a bioprosthetic valve is usually diagnosed in the early postoperative period, when endothelialisation of the suture zone is incomplete ([@bib1]). Although previously considered rare ([@bib2]), a recent observational study using cardiac CT imaging found an incidence of 4% (5/138) and 13% (101/752) in patients with surgical and transcatheter valves respectively ([@bib3]). We have had another two cases of sub-acute bioprosthetic valve leaflet thrombosis in our centre this year, highlighting that this condition is not as rare as previously thought. Anticoagulation therapy -- and not anti-platelet drugs -- was associated with successful prevention and treatment of subclinical leaflet thrombosis ([@bib3]). Indeed, American guidelines on valvular heart disease give a Class IIb recommendation for a period (3--6 months) of formal anticoagulation after bioprosthetic AVR ([@bib4]). Patients with established risk factors, including atrial fibrillation and a history of thromboembolic event, may have most to benefit from a brief period of routine post-operative anticoagulation ([@bib5]).Figure 1Mid-oesophageal short-axis (A) and long-axis (B) views of the bioprosthetic aortic valve demonstrating marked thickening of the leaflets (white arrows). Ao, aorta; LA, left atrium; LV, left ventricle; MV, mitral valve; RA, right atrium. Figure 2Mid-oesophageal short axis (A) and long axis (B) views of the bioprosthetic aortic valve on repeat TOE assessment, demonstrating thin and mobile valve leaflets (white arrows). (PA, pulmonary artery.) Figure 3Continuous wave Doppler traces across the bioprosthetic valve before (A) and after (B) 3 months of anticoagulation therapy. Markedly elevated gradients across the valve returned to normal after resolution of valve leaflet thrombosis.

Mid-oesophageal aortic short-axis view revealing marked thickening of the bioprosthetic valve cusps (green arrows). LA, left atrium; PV, pulmonary valve; RA, right atrium. View Video 1 at <http://movie-usa.glencoesoftware.com/video/10.1530/ERP-18-0032/video-1>.

Download Video 1

Mid-oesophageal aortic long axis view revealing marked thickening of the bioprosthetic valve cusps (green arrows). View Video 2 at <http://movie-usa.glencoesoftware.com/video/10.1530/ERP-18-0032/video-2>.

Download Video 2

Mid-oesophageal aortic short axis view revealing normal appearances of the bioprosthetic valve cusps (green arrows). PA, pulmonary artery. View Video 3 at <http://movie-usa.glencoesoftware.com/video/10.1530/ERP-18-0032/video-3>.

Download Video 3

Mid-oesophageal aortic long axis view revealing normal appearances of the bioprosthetic valve cusps (green arrows). View Video 4 at <http://movie-usa.glencoesoftware.com/video/10.1530/ERP-18-0032/video-4>.
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